KRAS and cancer: Oncogenic mutations in KRAS commonly occur at codons 12, 13, or 61 across various cancers, leading to constitutive activation independent of EGFR signaling and promoting oncogenic signaling through pathways such as the mitogen-activated protein kinase (MAPK) cascade.5